CardioGenics Holdings Inc. is focused on technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. The Company has developed the QL Care Analyzer, a point-of-care immuno-analyzer, which is capable of running approximately 200+immunoassay diagnostic tests, such as cardiovascular diagnostic tests. As part of its technology, the Company has also developed a method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improves instrument sensitivity to light.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 20:09:02 17/09/2026 +03			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		0.00%	-

10/09/21	Cardiogenics Holdings Inc Announces A Record Date Change for Its Dividend Distribution	CI
04/09/21	CardioGenics Holdings Inc. Announces License Agreement	CI

Market Cap	382K 333K 315K 286K 535K 36.6M 537K 3.75M 1.45M 18.6M 1.44M 1.4M 59.55M	P/E 2014	-2.3x	P/E 2015	-2.17x
Enterprise Value	539K 469K 444K 403K 754K 51.59M 757K 5.29M 2.05M 26.22M 2.02M 1.98M 83.93M	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	97.49%	Yield 2014 *	-	Yield 2015	-

10/09/21	Cardiogenics Holdings Inc Announces A Record Date Change for Its Dividend Distribution	CI
04/09/21	CardioGenics Holdings Inc. Announces License Agreement	CI
02/11/15	CardioGenics Holdings Inc completed the acquisition of substantially all of the assets of Plasticap Inc.	CI
05/10/15	CardioGenics Holdings Inc entered into a non-binding letter of intent to acquire substantially all of the assets of Plasticap Inc.	CI
13/01/15	CardioGenics Holdings Inc. Appoints Karim Murabet as Director	CI
27/09/13	CardioGenics Holdings Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2013	CI
21/08/13	CardioGenics Holdings Inc Announces Commencement of Beta-Site Testing	CI
05/06/13	CardioGenics Holdings Inc Announces Internal Review Board Approval for Beta-Site Testing	CI
03/06/13	CardioGenics Holdings Inc announced that it has received $0.66 million in funding.	CI
31/05/13	CardioGenics Holdings Inc announced that it expects to receive $1.5 million in funding.	CI
01/03/13	CardioGenics Holdings Inc. Announces Demise of Director, Alexander D. G. Reid	CI
27/02/13	CardioGenics Holdings Inc. announced that it expects to receive $1 million in funding.	CI
17/04/12	CardioGenics Holdings Inc has Changed its Ticker to CGNH from CGNHE	CI

29/09/21	UPDATED: CARDIOGENICS HOLDINGS INC. ANNOUNCES A RECORD DATE CHANGE FOR ITS DIVIDEND DISTRIBUTION	AQ
10/09/21	CARDIOGENICS : ANNOUNCES A RECORD DATE CHANGE FOR ITS DIVIDEND DISTRIBUTION	AQ
04/09/21	CARDIOGENICS : ANNOUNCES LICENSE AGREEMENT AND DIVIDEND DISTRIBUTION	AQ
04/11/15	CardioGenics : Enters Into Asset Purchase Agreement to Acquire All Assets of Ontario-Based Plasticap	MW
05/10/15	CardioGenics : Enters Into Binding Letter of Intent to Acquire Assets of Ontario-Based Plasticap	MW

CardioGenics Holdings Inc Stock

Stocks

CGNH

US14160X2036

Medical Equipment, Supplies & Distribution

Valuation: CardioGenics Holdings Inc

Chart: CardioGenics Holdings Inc

Latest news: CardioGenics Holdings Inc

Press Releases: CardioGenics Holdings Inc

Quotes and Performance

Price Extremes

Managers and Directors: CardioGenics Holdings Inc

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.05
10 years	0		0.29

Manager	Title	Age	Since
Yahia A. Gawad CEO	Chief Executive Officer	68	27/10/2009
James A. Essex DFI	Director of Finance/CFO	78	16/06/2010
Linda J. Sterling IRC	Investor Relations Contact	65	-

Director	Title	Age	Since
Yahia A. Gawad BRD	Director/Board Member	68	06/04/2011
Julian Neil Tabatznik CHM	Chairman	76	16/06/2010
Linda J. Sterling BRD	Director/Board Member	65	16/06/2010

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARDIOGENICS HOLDINGS INC	-99.00%	0.00%	-	-	142
GUARDANT HEALTH, INC.	+4.69%	+15.14%	+220.16%	+520.05%	24.57B
BIOMÉRIEUX	-0.48%	+0.70%	-36.53%	-21.55%	9.74B
10X GENOMICS, INC.	+5.90%	+15.95%	+498.52%	+54.78%	10.03B
CARIS LIFE SCIENCES, INC.	+9.61%	+28.62%	-7.78%	-	8.74B
LANTHEUS HOLDINGS, INC.	+0.26%	+0.41%	+98.27%	+55.53%	6.58B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.22%	+1.87%	-29.50%	-24.49%	5.75B
DIASORIN S.P.A.	+1.30%	+3.61%	-3.12%	-17.22%	4.33B
ANDON HEALTH CO., LTD.	+0.95%	-3.17%	+53.60%	+64.65%	3.78B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.78%	+0.09%	-21.43%	-30.67%	2.74B
Average	-7.58%	+6.80%	+85.80%	+75.13%	7.63B
Weighted average by Cap.	+3.51%	+10.76%	+138.89%	+198.86%

	2014	2015
Net sales	-	-
Net income	-2.68M -2.33M -2.21M -2.01M -3.75M -257M -3.77M -26.31M -10.17M -130M -10.07M -9.84M -418M	-1.92M -1.67M -1.58M -1.44M -2.68M -184M -2.69M -18.82M -7.28M -93.27M -7.2M -7.04M -299M
Net Debt	132K 115K 109K 99.04K 185K 12.66M 186K 1.3M 502K 6.44M 497K 486K 20.6M	157K 136K 129K 117K 219K 14.99M 220K 1.54M 594K 7.62M 588K 575K 24.39M